MSLE net incomeFY2025-$24.87M
MSLE net income was -$24.87M for fiscal 2025 (ended Dec 31, 2025), compared with -$20.63M in fiscal 2024.
Satellos Bioscience Inc. (MSLE) financials
For fiscal 2025 (ended Dec 31, 2025), Satellos Bioscience Inc. reported -$24.87M of net income.
- Net income, FY2025
- -$24.87M
- Free cash flow, FY2025
- -$23.60M
- EPS, diluted, FY2025
- -$1.70
- Cash
- $9.80M
- Market cap
- $158.9M
FY2024FY2025
FY2024FY2025
MSLE revenue and earnings growth
MSLE EPSFY2025-$1.70
MSLE diluted EPS was -$1.70 for fiscal 2025 (ended Dec 31, 2025).
MSLE free cash flowFY2025-$23.60M
MSLE free cash flow was -$23.60M for fiscal 2025 (ended Dec 31, 2025), compared with -$18.26M in fiscal 2024.
Income statement
| Line item | Dec 31, 2025 | Dec 31, 2024 |
|---|---|---|
| Research and development | $18.43M | $14.36M |
| Selling, general and admin | $8.03M | $6.04M |
| Operating income | -$26.46M | -$20.40M |
| Pre-tax income | -$24.70M | -$20.63M |
| Income tax | $172.0K | - |
| Net income | -$24.87M | -$20.63M |
| EPS, basic | -$1.70 | -$2.16 |
| EPS, diluted | -$1.70 | -$2.16 |
| Diluted shares | 14.6M | 9.6M |
Balance sheet
| Line item | Dec 31, 2025 | Dec 31, 2024 |
|---|---|---|
| Cash and equivalents | $9.80M | $40.07M |
| Current assets | $31.88M | $50.74M |
| Total assets | $31.89M | $50.75M |
| Current liabilities | $4.11M | $3.58M |
| Total liabilities | $4.11M | $3.58M |
| Shareholders' equity | $27.78M | $47.16M |
Cash flow
| Line item | Dec 31, 2025 | Dec 31, 2024 |
|---|---|---|
| Operating cash flow | -$23.60M | -$18.25M |
| Capital expenditures | $6.0K | $4.0K |
| Free cash flow | -$23.60M | -$18.26M |
| Investing cash flow | -$9.42M | $4.66M |
| Financing cash flow | $2.24M | $37.57M |
| Stock-based compensation | $3.23M | $1.64M |
Key ratios
Source: XBRL data Satellos Bioscience Inc. files with the SEC, latest filing dated Mar 27, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
Per-share figures are as filed. The filings show no stock split in these periods.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
Foreign private issuers file annual reports with the SEC, so there are no quarterly statements here.
MSLE peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| MSLE | - | - | -$24.87M | - | $158.9M |
| LLY | $86.46B | +45.5% | $27.58B | 31.9% | $1.33T |
| JNJ | $99.33B | +7.8% | $16.09B | 16.2% | $679.13B |
| ABBV | $66.01B | +10.7% | $10.34B | 15.7% | $518.44B |
| MRK | $67.38B | +4.9% | $2.45B | 3.6% | $366.73B |
| NVS | $54.53B | +8.4% | $13.98B | 25.6% | $312.35B |
| AZN | $58.74B | +8.6% | $10.22B | 17.4% | $293.69B |
| ABT | $48.23B | +10.0% | $4.70B | 9.7% | $191.40B |
| NVO | DKK 309.06B | +6.4% | DKK 102.43B | 33.1% | $183.23B |
MSLE FAQ
6 questionsIs MSLE profitable?
No. Satellos Bioscience Inc. reported a net loss of $24.87M for fiscal 2025 (ended Dec 31, 2025).How much cash and debt does MSLE have?
Satellos Bioscience Inc. reported $9.80M in cash and cash equivalents on its most recent balance sheet in SEC filings.What is MSLE free cash flow?
Satellos Bioscience Inc. generated -$23.60M of free cash flow for fiscal 2025 (ended Dec 31, 2025), which is operating cash flow of -$23.60M less capital expenditures.What is MSLE earnings per share?
Diluted earnings per share were -$1.70 for fiscal 2025 (ended Dec 31, 2025), from SEC filings, restated for any stock split those filings show.When did MSLE last report financial results?
The latest statements here come from Satellos Bioscience Inc.'s 40-F filed on Mar 27, 2026, covering the period ended Dec 31, 2025.Where does this MSLE financial data come from?
Quantisnow builds these statements from the structured XBRL data Satellos Bioscience Inc. files with the SEC. It is provided for information only and is not investment advice.